LPS-induced murine neuroinflammation model: Main features and suitability for pre-clinical assessment of nutraceuticals

Current Neuropharmacology

Volumn 14, Issue 2, 2016, Pages 155-164

  Catorce, Miryam Nava ^a   Gevorkian, Goar ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Astrocytes; LPS; Microglia; Neurodegeneration; Neuroinflammation; Nutraceuticals

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CURCUMIN; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; FLAVONOID; GINSENOSIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCYRRHIZIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NUTRACEUTICAL; OENOTHEIN B; RESVERATROL; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; LIPOPOLYSACCHARIDE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ASTROCYTOSIS; BLOOD BRAIN BARRIER; CELL ACTIVATION; COGNITIVE DEFECT; DISEASE EXACERBATION; FRONTOTEMPORAL DEMENTIA; LIPOPOLYSACCHARIDE INDUCED NEUROINFLAMMATION; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SYNAPSE; ANIMAL; ASTROCYTE; BRAIN; CHEMICALLY INDUCED; COMPLICATION; DEGENERATIVE DISEASE; DIETARY SUPPLEMENT; DISEASE MODEL; DRUG EFFECTS; ENCEPHALITIS; METABOLISM; MOUSE; REPRODUCIBILITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTROCYTES; BRAIN; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ENCEPHALITIS; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; NEURODEGENERATIVE DISEASES; REPRODUCIBILITY OF RESULTS;

EID: 84960100837     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159x14666151204122017     Document Type: Review

References (140)

1. Philips, T.; Robberecht, W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol., 2011, 10(3), 253-263. http://dx.doi.org/10.1016/S1474-4422(11)70015-1
2. Eikelenboom, P.; Hoozemans, J.J.; Veerhuis, R.; van Exel, E.; Rozemuller, A.J.; van Gool, W., A. Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer´s disease. Alzheimers Res. Ther., 2012, 4(3), 15. http://dx.doi.org/10.1186/alzrt118
3. Blandini, F. Neural and immune mechanisms in the pathogenesis of Parkinson’s disease. J. Neuroimmune Pharmacol., 2013, 8(1), 189-201. http://dx.doi.org/10.1007/s11481-013-9435-y
4. Evans, M.C.; Couch, Y.; Sibson, N.; Turner, M.R. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol. Cell. Neurosci., 2013, 53, 34-41. http://dx.doi.org/10.1016/j.mcn.2012.10.008
5. Krstic, D.; Knuessel, I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol., 2013, 9(1), 25-34. http://dx.doi.org/10.1038/nrneurol.2012.236
6. Murta, V.; Ferrari, C.C. Influence of peripheral inflammation on the progression of multiple sclerosis: evidence from clinic and experimental animal models. Mol. Cell. Neurosci., 2013, 53, 6-13. http://dx.doi.org/10.1016/j.mcn.2012.06.004
7. Amor, S.; Peferoen, L.A.; Vogel, D.Y.; van der Valk, P.; Baker, D.; van Noort, J.M. Inflammation in neurodegenerative diseases – an update. Immunology, 2014, 142(2), 151-166. http://dx.doi.org/10.1111/imm.12233
8. Heneka, M.T.; Kummer, M.P.; Latz, E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol., 2014, 14(7), 463-477. http://dx.doi.org/10.1038/nri3705
9. Pasqualetti, G.; Brooks, D.J.; Edison, P. The role of neuroinflammation in dementias. Curr. Neurol. Neurosci. Rep., 2015, 15(4), 17. http://dx.doi.org/10.1007/s11910-015-0531-7
10. Luterman, J.D.; Haroutunian V.; Yemul, S.; Ho, L.; Purohit, D.; Aisen, P.S.; Mohs, R.; Pasinetti, G.M. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch. Neurol., 2000, 57(8), 1153-1160. http://dx.doi.org/10.1001/archneur.57.8.1153
11. Serrano-Pozo, A.; Mielke, M.L.; Gomez-Isla, T.; Betensky, R.A.; Growdon, J.H.; Frosch, M.P.; Hyman, B.T. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer´s disease. Am. J. Pathol., 2011, 179(3), 1373-1384. http://dx.doi.org/10.1016/j.ajpath.2011.05.047
12. McGeer, P.L.; McGeer, E.G. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol., 2013, 126(4), 479-497. http://dx.doi.org/10.1007/s00401-013-1177-7
13. Exalto, L.G.; Whitmer, R.A.; Kappele, L.J.; Biessels, G.J. An update on type 2 diabetes, vascular dementia and Alzheimer´s disease. Exp. Gerontol., 2012, 47(11), 858-864. http://dx.doi.org/10.1016/j.exger.2012.07.014
14. Ledesma, M.D.; Dotti, C.G. Peripheral cholesterol, metabolic disorders and Alzheimer´s disease. Front. Biosci., 2012, 4, 181-194. http://dx.doi.org/10.2741/E368
15. Misiak, B.; Leszek, J.; Kiejna, A. metabolic syndrome, mild cognitive impairment and Alzheimer´s disease – the emerging role of systemic low-grade inflammation and adiposity. Brain Res. Bull., 2012, 89(3-4), 144-149. http://dx.doi.org/10.1016/j.brainresbull.2012.08.003
16. Polidori, M.C.; Pientka, L.; Mecocci, P. A review of the major vascular risk factors related to Alzheimer´s disease. J. Alzheimers Dis., 2012, 32(3), 521-530.
17. Spielman, L.J.; Little, J.P.; Klegeris, A. Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. J. Neuroimmunol., 2014, 273(1-2), 8-21. http://dx.doi.org/10.1016/j.jneuroim.2014.06.004
18. Holmes, C.; Cotterell, D. Role of infection in the pathogenesis of Alzheimer´s disease: implications for treatment. CNS Drugs, 2009, 23(12), 993-1002. http://dx.doi.org/10.2165/11310910-000000000-00000
19. Holmes, C. Review: systemic inflammation and Alzheimer´s disease. Neuropathol. Appl. Neurobiol., 2013, 39(1), 51-68. http://dx.doi.org/10.1111/j.1365-2990.2012.01307.x
20. Su, X.; Federoff, H.J. Immune responses in Parkinson´s disease: interplay between central and peripheral immune systems. Biomed. Res. Int., 2014, 2014, 275178.
21. Magrone, T.; Marzulli, G.; Jirillo, E. Immunopathogenesis of neurodegenerative diseases: current therapeutic models of neuroprotection with special reference to natural products. Curr. Pharm. Des., 2012, 18(1), 34-42. http://dx.doi.org/10.2174/138161212798919057
22. Qin, L.; Wu, X.; Block, M.L.; Liu, Y.; Breese, G.R.; Hong, J.S.; Knapp, D.J.; Crews, F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia, 2007, 55(5), 453-462. http://dx.doi.org/10.1002/glia.20467
23. Erickson, M.A.; Banks, W.A. Cytokine and chemokine responses in serum and brain after single and repeated injections of lipopolysaccharide: multiplex quantification with path analysis. Brain Behav. Immun., 2011, 25(8), 1637-1648. http://dx.doi.org/10.1016/j.bbi.2011.06.006
24. Park, S.M.; Choi, M.S.; Sohn, N.W.; Shin, J.W. Ginsenoside Rg3 attenuates microglia activation following systemic lipopolysaccharide treatment in mice. Biol. Pharm. Bull., 35(9), 1546-1552. http://dx.doi.org/10.1248/bpb.b12-00393
25. Biesmans, S.; Meert, T.F.; Bouwknecht, J.A.; Acton, P.D.; Davoodi, N.; De Haes, P.; Kuijlaars, J.; Langlois, X.; Matthews, L. J.; Ver Donck, L.; Hellings, N.; Nuydens, R. Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators Inflamm., 2013, 2013, 271359.
26. Sheng, J.G.; Bora, S.H.; Xu, G.; Borchelt, D.R.; Price, D.L.; Koliatsos, V.E. Lipopolysaccharide-induced neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid β peptide in APPswe transgenic mice. Neurobiol. Dis., 2003, 14, 133-145. http://dx.doi.org/10.1016/S0969-9961(03) 00069-X
27. Kitazawa, M.; Oddo, S.; Yamasaki, T.R.; Green, K.N.; LaFerla, F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer´s disease. J. Neurosci., 2005, 25(39), 8843-8853. http://dx.doi.org/10.1523/JNEUROSCI.2868-05.2005
28. Schwartz, M.; Kipnis, J.; Rivest, S.; Prat, A. How do immune cells support and shape the brain in health, disease, and aging? J. Neurosci., 2013, 33(45), 17587-17596. http://dx.doi.org/10.1523/JNEUROSCI.3241-13.2013
29. Nayak, D.; Roth, T.L.; McGavern, D.B. Microglia development and function. Annu. Rev. Immunol., 2014, 32, 367-402. http://dx. doi.org/10.1146/annurev-immunol-032713-120240
30. Casano, A.M.; Peri, F. Microglia: multitasking specialists of the brain. Dev. Cell, 2015, 32(4), 469-477. http://dx.doi.org/10.1016/j.devcel.2015.01.018
31. Benakis, C.; Garcia-Bonilla, L.; Iadecola, C.; Anrather, J. The role of microglia and myeloid immune cells in acute cerebral ischemia. Front. Cell. Neyrosci., 2015, 8, 461. http://dx.doi.org/10.3389/fncel.2014.00461
32. Tremblay, M.E.; Stevens, B.; Sierra, A.; Wake, H.; Bessis, A.; Nimmerjahn, A. The role of microglia in the healthy brain. J. Neurosci., 2011, 31(45), 16064-16069. http://dx.doi.org/10.1523/JNEUROSCI.4158-11.2011
33. Sy, M.; Kitazawa, M.; Medeiros, R.; Whitman, L.; Cheng, D.; Lane, T.E.; LaFerla., F.M. Inflammation induced by infection potentiates pathological features in transgenic mice. Am. J. Pathol., 2011, 178(6), 2811-2822. http://dx.doi.org/10.1016/j.ajpath.2011.02.012
34. Ifuku, M.; Katafuchi, T.; Mawatari, S.; Noda, M.; Miake, K.; Sugiyama, M.; Fujino, T. Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice. J. Neuroinflamm., 2012, 9, 197. http://dx.doi.org/10.1186/1742-2094-9-197
35. Okuyama, S.; Makihata, N.; Yoshimura, M.; Amakura, Y.; Yoshida, T.; Nakajima, M.; Furukawa, Y. Oenothein B suppresses lipopolysaccharide (LPS)-induced inflammation in mouse brain. Int. J. Mol. Sci., 2013, 14, 9767-9778. http://dx.doi.org/10.3390/ijms14059767
36. Jin, M.; Jang, E.; Suk, K. Lipocalin-2 acts as a neuroinflammatogen in lipopolysaccharide-injected mice. Exp. Neurobiol., 2014, 23(2), 155-162. http://dx.doi.org/10.5607/en.2014.23.2.155
37. Cunningham, C.; Wilcockson, D. C.; Campion, S.; Lunnon, K.; Perry, V. H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci., 2005, 25(40), 9275-9284. http://dx.doi.org/10.1523/JNEUROSCI.2614-05.2005
38. Chen, Z.; Jalabi, W.; Shpargel, K.B.; Farabaugh, K.T.; Dutta, R.; Yin, X.; Kidd, G.J.; Bergmann, C.C.; Stohlman, S.A.; Trapp, B.D. Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent on hematogenous TLR4. J. Neurosci., 2012, 32(34), 11706-11715. http://dx.doi.org/10.1523/JNEUROSCI.0730-12.2012
39. Elmquist, J.K.; Scammell, T.E.; Saper, C.B. Mechanisms of CNS response to systemic immune challenge: the febrile response. Trends Neurosci., 1997, 20(12), 565-570. http://dx.doi.org/10.1016/S0166-22369701138-7
40. Vallieres, L.; Rivest, S. Regulation of the genes encoding interleukin-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and proinflammatory cytokine interleukin-1beta. J. Neurochem., 1997, 69(4), 1668-1683. http://dx.doi.org/10.1046/j.1471-4159.1997.69041668.x
41. Lacroix, S.; Rivest, S. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. J. Neurochem., 1998, 70(2), 452-466. http://dx.doi.org/10.1046/j.1471-4159.1998.70020452.x
42. Laye, S.; Parnet, P.; Goujon, E.; Dantzer, R. Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Brain Res. Mol. Brain Res., 1994, 27(1), 157-162. http://dx.doi.org/10.1016/0169-328X(94)90197-X
43. Brugg, B.; Dubreuil, Y.L.; Huber, G.; Wollman, E.E.; Delhaye-Bouchaud, N.; Mariani, J. Inflammatory processes induce betaamyloid precursor protein changes in mouse brain. Proc. Natl. Acad. Sci. USA, 1995, 92(7), 3032-3035. http://dx.doi.org/10.1073/pnas.92.7.3032
44. Gabellec, M.M.; Griffais, R.; Fillion, G.; Haour, F. Expression of interleukin 1 alpha, interleukin 1 beta and interleukin 1 receptor antagonist mRNA in mouse brain: regulation by bacterial lipopolysaccharide (LPS) treatment. Brain Res. Mol. Brain Res., 1995, 31(1-2), 122-130. http://dx.doi.org/10.1016/0169-328X(95)00042-Q
45. Pitossi, F.; del Rey, A.; Kabiersch, A.; Besedovsky, H. Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J. Neurosci. Res., 1997, 48(4), 287-298. http://dx.doi.org/10.1002/(SICI)1097-4547(19970515)48:4%3C287::AIDJNR1% 3E3.0.CO;2-7
46. Ban, E.; Haour, F.; Lenstra, R. Brain interleukin 1 gene expression induced by peripheral lipopolysaccharide administration. Cytokine, 1992, 4(1), 48-54. http://dx.doi.org/10.1016/1043-4666(92)90036-Q
47. Takao, T.; Culp, S.G.; De Souza, E.B. Reciprocal modulation of interleukin-1 beta (IL-1beta) and IL-1 receptors by lipopolysaccharide (endotoxin) treatment in the mouse brainendocrine-immune axis. Endocrinology, 1993, 132(4), 1497-1504.
48. Kishikawa, H.; Lawrence, D.A. Differential production of interleukin-6 in the brain and spleen of mice treated with lipopolysaccharide in the presence and absence of lead. J. Toxicol. Environ. Health A., 1998, 53(5), 357-373. http://dx.doi.org/10.1080/009841098159222
49. Brochu, S.; Olivier, M.; Rivest, S. Neuronal activity and transcription of proinflammatory cytokines, IkappaBalpha, and iNOS in the mouse brain during acute endotoxemia and chronic infection with Trypanosoma brucei brucei. J. Neurosci. Res., 1999, 57(6), 801-816. http://dx.doi.org/10.1002/(SICI)1097-4547(19990915)57:6%3C801::AID-JNR5%3E3.0.CO;2-B
50. Godbout, J.P.; Chen, J.; Abraham, J.; Richwine, A.F.; Berg, B.M.; Kelley, K.W.; Jphnson, R.W. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J., 2005, 19(10), 1329-1331.
51. Chen, J.; Buchanan, J.B.; Sparkman, N.L.; Godbout, J.P.; Freund, G.G.; Johnson, R.W. Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav. Immun., 2008, 22, 301-311. http://dx.doi.org/10.1016/j.bbi.2007.08.014
52. Henry, C.J.; Huang, Y.; Wynne, A.M.; Godbout, J.P. Peripheral lipopolysaccharide (LPS) challenge promotesmicroglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1β and anti-inflammatory IL-10 cytokines. Brain Behav. Immun., 2009, 23, 309-317. http://dx.doi.org/10.1016/j.bbi.2008.09.002
53. Ip, J.P.; Nocon, A.L.; Hofer, M.J.; Lim, S.L.; Muller, M.; Campbell, I.L. Lipocalin 2 in the central nervous system host response to systemic lipopolysaccharide administration. J. Neuroinflammation, 2011, 8, 124. http://dx.doi.org/10.1186/1742-2094-8-124
54. Fu, Y.Y.; Zhang, F.; Zhang, L.; Liu, H.Z.; Zhao, Z.M.; Wen, X.R.; Wu, J.; Qi, D.S.; Sun, Y.; Du, Y.; Dong, H.Y.; Liu, Y.H.; Song, Y.J. Mangiferin regulates interleukin-6 and cystathionine-bsynthase in lipopolysaccharide-induced brain injury. Cell. Mol. Neurobiol., 2014, 34(5), 651-657. http://dx.doi.org/10.1007/s10571-014-0039-8
55. Cazareth, J.; Guyon, A.; Heurteaux, C.; Chabry, J.; Petit-Paitel, A. Molecular and cellular neuroinflammatory status of mouse brain after systemic lipopolysaccharide challenge: importance of CCR2/CCL2 signaling. J. Neuroinflamm., 2014, 11, 132.http://dx. doi.org/10.1186/1742-2094-11-132
56. Francois, A.; Terro, F.; Quellard, N.; Fernandez, B.; Chassaing, D.; Janet, T.; Rioux-Bilan, A.; Paccalin, M.; Page, G. Impairment of autophagy in the central nervous system during lipopolysaccharideinduced inflammatory stress in mice. Mol. Brain, 2014, 7(1), 56. http://dx.doi.org/10.1186/s13041-014-0056-z
57. Wohleb, E.S.; Fenn, A.M.; Pacenta, A.M.; Powell, N.D.; Sheridan, J.F.; Godbout, J.P. Peripheral innate immune challenge exaggerated microglia activation, increased the number of inflammatory CNS macrophages, and prolonged social withdrawal in socially defeated mice. Psyconeuroendocrinology, 2012, 37(9), 1491-1505. http://dx.doi.org/10.1016/j.psyneuen.2012.02.003
58. Biesmans, S.; Acton, P.D.; Cotto, C.; Langlois, X.; Donck, L.V.; Bouwknecht, J.A.; Aelvoet, S.A.; Hellings, N.; Meert, T.F.; Nuydens, R. Effect of stress and peripheral immune activation on astrocyte activation in transgenic bioluminescent Gfap-luc mice. Glia, 2015, 63, 1126-1137. http://dx.doi.org/10.1002/glia.22804
59. Hopkins, W.; Gendron-Fitzpatrick, A.; McCarthy, D.O.; Haine, J.E.; Uehling, D.T. Lipopolysaccharide-responder and nonresponder C3H mouse strains are equally susceptible to an induced Escherichia coli urinary tract infection. Infect. Immun., 1996, 64(4), 1369-1372.
60. De Maio, A.; Mooney, M.L.; matesic, L.E.; Paidas, C.N.; Reeves, R.H. Genetic component in the inflammatory response induced by bacterial lipopolysaccharide. Shock, 1998, 10(5), 319-323. http://dx.doi.org/10.1097/00024382-199811000-00002
61. Yang, I.V.; Rutledge, H.R.; Yang, J.; Warg, L.A.; Sevilla, S.D.; Schwartz, D.A. A locus on chromosome 9 is associated with defferential response of 129S1/SvlmJ and FVB/NJ strains of mice to systemic LPS. Mamm. Genome, 2011, 22(9-10), 518-529. http://dx.doi.org/10.1007/s00335-011-9340-8
62. Yang, I.V.; Alper, S.; Lackford, B.; Rutledge, H.; Warg, L.A.; Burch, L.H.; Schwatrz, D.A. Novel regulators of the systemic response to lipopolysaccharide. Am. J. Respir. Cell. Mol. Biol., 2011, 45(2), 393-402. http://dx.doi.org/10.1165/rcmb.2010-0342OC
63. Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, C.; Harigaya, Y.; Younkin, S.; Yang, F.; Cole, G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science, 1996, 274(5284), 99-102. http://dx.doi.org/10.1126/science.274.5284.99
64. irizzary, M.C.; McNamara, M.; Fedorchak, K.; Hsiao, K.; hyman, B.T. APPSwe transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol., 1997, 56(9), 965-973. http://dx.doi.org/10.1097/00005072-199709000-00002
65. Johnson-Wood, K.; Lee, M.; Motter, R.; Hu, K.; Gordon, G.; Barbour, R.; Khan, K.; Gordon, M.; Tan, H.; Games, D.; Leiberburg, I.; Schenk, D.; Seubert, P.; McConlogue, L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1997, 94(4), 1550-1555. http://dx.doi.org/10.1073/pnas.94.4.1550
66. Masliah, E.; Rockenstein, E. Genetically altered transgenic models of Alzheimer´s disease. J. Neural. Transm. Suppl., 2000, 59, 175-183. http://dx.doi.org/10.1007/978-3-7091-6781-6_20
67. Oddo, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; LaFerla, F. M. Triple-transgenic model of Alzheimer´s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 2003, 39(3), 409-421. http://dx.doi.org/10.1016/S0896-6273(03)00434-3
68. German, D.C.; Nelson, O.; Liang, F.; Liang, C.L.; Games, D. The PDAPP mouse model of Alzheimer´s disease: locus coeruleus neuronal shrinkage. J. Comp. Neurol., 2005, 492(4), 469-476. http://dx.doi.org/10.1002/cne.20744
69. Meredith, G.E.; Totterdel, S.; Potshkin, J.A.; Surmeier, D.J. Modelling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord., 2008, 14(Suppl 2), S112-115. http://dx.doi.org/10.1016/j.parkreldis.2008.04.012
70. Crews, L.; Rockenstein, E.; masliah, E. APP transgenic modeling of Alzheimer´s disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct. Funct., 2010, 214(3-4), 116-126.
71. Bove, J.; Perier, C. Neurotoxin-based models of Parkinson´s disease. Neuroscience, 2012, 211, 51-76. http://dx.doi.org/10.1016/j.neuroscience.2011.10.057
72. Chesselet, M.F.; Richter, F.; Zhu, C.; Magen, I.; Watson, M.B.; Subramanian, S.R. A progressive mouse model of Parkinson´s disease: the Thy1-aSyn (“Line61”) mice. Neurotherapeutics, 2012, 9(2), 297-314. http://dx.doi.org/10.1007/s13311-012-0104-2
73. Chaboub, L.S.; Deneen, B. Developmental origins of astrocyte heterogeneity: The final frontier of CNS development. Dev. Neurosci., 2012, 34(5), 379-388. http://dx.doi.org/10.1159/000343723
74. Sofroniew, M.V. Astrocyte barriers to neurotoxic inflammation. Nat. Rev. Neurosci., 2015, 16(5), 249-263. http://dx.doi.org/10.1038/nrn3898
75. Sofroniew, M.V. Astrogliosis. Cold Spring Harb. Perspect. Biol., 2015, 7, a020420. http://dx.doi.org/10.1101/cshperspect.a020420
76. Kang, W.; Hebert, J.M. Signaling pathways in reactive astrocytes, a genetic perspective. Mol. Neurobiol., 2011, 43, 147-154. http://dx. doi.org/10.1007/s12035-011-8163-7
77. Burda, J.E.; Sofroniew, M.V. Reactive gliosis and the multicellular response to CNS damaga and disease. Neuron, 2014, 81(2), 229-248. http://dx.doi.org/10.1016/j.neuron.2013.12.034
78. Camara, M.L.; Corrigan, F.; Jaehne, E.J.; Jawahar, M.C.; Anscomb, H.; Baune, B.T. Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsycopharmacology, 2015, 40, 502-512. http://dx.doi.org/10.1038/npp.2014.199
79. Dubois, R.N.; Abramson, S.B.; Crofford, L.; Gupta, R.A.; Simon, L.S.; van de Putte, L.B.A.; Lipsky, P.E. Cyclooxygenase in biology and disease. FASEB J., 1998, 12, 1063-1073.
80. Heneka, M.T.; Feinstein, D.L. Expression and function of inducible nitric oxide synthase in neurons. J. Neuroimmunol., 2001, 114(1-2), 8-18. http://dx.doi.org/10.1016/S0165-5728(01)00246-6
81. Minghetti, L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol., 2004, 63(9), 901-910. http://dx.doi.org/10.1093/jnen/63.9.901
82. Brown, G.C. Mechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase. Biochem. Soc. Trans., 2007, 35, 1119-1121. http://dx.doi.org/10.1042/BST0351119
83. Doherty, G.H. Nitric oxide in neurodegeneration: potential benefits on non-steroidal anti-inflammatories. Neurosci. Bull., 2011, 27(6), 366-382. http://dx.doi.org/10.1007/s12264-011-1530-6
84. Lassmann, H. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer´s disease. J. Neural. Transm., 2011, 118(5), 747-752. http://dx.doi.org/10.1007/s00702-011-0607-8
85. Drechsel, D.A.; Estevez, A.G.; Barbeito, L.; Beckman, J.S. Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS. Neurotox. Res., 2012, 22(4), 251-264. http://dx.doi.org/10.1007/s12640-012-9322-y
86. Nathan, C.; Calingasan, N.; Nezezon, J.; Ding, A.; Lucia, M.S.; La Perle, K.; Fuortes, M.; Lin, M.; Ehrt, S.; Kwon, N. S.; Chen, J.; Vodovotz, Y.; Kipiani, K.; Beal, M.F. protection from Alzheimer´s-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J. Exp. Med., 2005, 202(9), 1163-1169. http://dx.doi.org/10.1084/jem.20051529
87. Tomaz, V.S.; Cordeiro, R.C.; Costa, A.M.; de Lucena, D. F.; Nobre Junior, H.V.; de Sousa, F.C.; Vasconcelos, S.M.; Vale, M.L.; Quevedo, J.; Macedo, D. Antidepressant-like effect of nitric oxide synthase inhibitors and sildenafil against lipopolysaccharideinduced depressive-like behavior in mice. Neuroscience, 2014, 268, 236-246. http://dx.doi.org/10.1016/j.neuroscience.2014.03.025
88. Sapirstein, A.; Saito, H.; Texel, S.J.; Samad, T.A.; ÓLeary, E.; Bonventre, J.V. Cytosolic phospholipase A2α regulates induction of brain cyclooxygenase-2 in a mouse model of inflammation. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 288, R1774-R1782. http://dx.doi.org/10.1152/ajpregu.00815.2004
89. Dunn, A.J.; Swiergiel, A.H.; Zhang, H.; Quan, N. Reduced ingestion of sweetened milk induced by interleukin-1 and lipopolysaccharide is associated with induction of cyclooxygenase-2 in brain endothelia. Neuroimmunomodulation, 2006, 13(2), 96-104. http://dx.doi.org/10.1159/000096291
90. Czapski, G.A.; Gajkowska, B.; Strosznajder, J.B. Systemic administration of lipopolysaccharide induces molecular and morphological alterations in the hippocampus. Brain Res., 2010, 1356, 85-94. http://dx.doi.org/10.1016/j.brainres.2010.07.096
91. Chung, D.W.; Yoo, K.Y.; hwang, I.K.; Kim, D.W.; Chung, J.Y.; Lee, C.H.; Choi, J.H.; Youn, H.Y.; Lee, I.S.; Won, M.H. Systemic administration of lipopolysaccharide induces cyclooxygenase-2 immunoreactivity in endothelium and increases microglia in the mouse hippocampus. Cell. Mol. Neurobiol., 2010, 30(4), 531-541. http://dx.doi.org/10.1007/s10571-009-9477-0
92. Song, J.H.; Lee, J.W.; Shim, B.; Lee, C.Y.; Choi, S.; Kang, C.; Sohn, N.W.; Shin, J.W. Glycyrrhizin alleviates neuroinflammation and memory deficit induced by systemic lipopolysaccharide treatment in mice. Molecules, 2013, 18, 15788-15803. http://dx. doi.org/10.3390/molecules181215788
93. Laflamme, N.; Lacroix, S.; Rivest, S. An essential role of interleukin-1β in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J. Neurosci., 1999, 19(24), 10923-10930.
94. Zinetti, M.; Benigni, F.; Sacco, S.; minto, M.; Galli, G.; Salmona, S.; Andreoni, G.; Vezzni, A.; Ghezzi, P.; Fratelli, M. Regional production of nitric oxide after peripheral or central low dose of LPS in mice. Neuroimmunomodulation, 1996, 3(6), 364-370. http://dx.doi.org/10.1159/000097297
95. Palin, K.; Bluthe, R.M.; Verrier, D.; Tridon, V.; Dantzer, R.; Lestage, J. Interleukin-1β mediates the memory impairment associated with delayed type hypersensitivity reponse to bacillus Calmette-Guerin in the rat hippocampus. Brain Behav. Immun., 2004, 18(3), 223-230. http://dx.doi.org/10.1016/j.bbi.2003.09.002
96. Sparkman, N.L.; Buchanan, J.B.; Heyen, J.R.R.; Chen, J.; Beverly, J.L.; Johnson, R.W. Interleukin-6 facilitates lipopolysaccharideinduced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J. Neurosci., 2006, 26(42), 10709-10716. http://dx.doi.org/10.1523/JNEUROSCI.3376-06.2006
97. Mandolesi, G.; Grasseli, G.; Musumeci, G.; Centonze, D. Cognitive deficits in experimental autoimmune encephalomyelitis: neuroinflammation and synaptic degeneration. Neurol. Sci., 2010, 31(Suppl 2), S255-S259. http://dx.doi.org/10.1007/s10072-010-0369-3
98. Jain, N.K.; Patil, C.S.; Kulkarni, S. K.; Singh, A. Modulatory role of cyclooxygenase inhibitors in aging-and scopolamine or lipopolysaccharide-induced cognitive disfunction in mice. Behav. Brain. Res., 2002, 133, 369-376. http://dx.doi.org/10.1016/S0166-4328(02)00025-6
99. Sparkman, N.L.; Martin, L.A.; Calvert, W.S.; Boehm, G.W. Effects of intraperitoneal lipopolysaccharide on Morris maze performance year-old and 2-month-old female C57BL/6J mice. Behav. Brain Res., 2005, 159, 145-151. http://dx.doi.org/10.1016/j.bbr.2004.10.011
100. Schnydrig, S.; Korner, L.; Landweer, S.; Ernst, B.; Walker, G.; Otten, U.; Kunz, D. Peripheral lipopolysaccharide administration transiently affects expression of brain-derived neurotrophic factor, corticotropin and proopiomelanocortin in mouse brain. Neurosci. Lett., 2007, 429(1), 69-73. http://dx.doi.org/10.1016/j.neulet.2007.09.067
101. Kohman, R.A.; Tarr, A.J.; Sparkman, N.L.; day, C.E.; paquet, A.; Akkaraju, G.R.; Boehm, G.W. Alleviation of the effects of endotoxin exposure on behavior and hippocampal IL-1b by a selective non-peptide antagonist of corticotropin-releasing factor receptors. Brain Behav. Immun., 2007, 21, 824-835. http://dx.doi.org/10.1016/j.bbi.2007.01.009
102. Ormerod, B.K.; Hanft, S.J.; Asokan, A.; Haditsch, U.; Lee, S.W.; Palmer, T.D. PPARg activation prevents impairments in spatial memory and neurogenesis following transient illness. Brain Behav. Immun., 2013, 29, 28-38. http://dx.doi.org/10.1016/j.bbi.2012.10.017
103. Valero, J.; Mastrella, G.; Neiva, I.; Sanchez, S.; Malva, J.A. Longterm effects of an acute and systemic administration of LPS on adult neurogenesis and spatial memory. Front. Neurosci., 2014, 8, 83. http://dx.doi.org/10.3389/fnins.2014.00083
104. Choi, D.K.; Koppula, S.; Suk, K. Inhibitors of microglial neurotoxicity: focus on natural products. Molecules, 2011, 16(2), 1021-1043. http://dx.doi.org/10.3390/molecules16021021
105. Ray, B.; Chauhan, N.B.; Lahiri, D.K. The “aged garlic extract”: (AGE) and one of its active ingredients S-allyl-L-cysteine (SAC) as potential preventive and therapeutic agents for Alzheimer´s disease (AD). Curr. Med. Chem., 2011, 18(22), 3306-3313. http://dx.doi.org/10.2174/092986711796504664
106. Essa, M.M.; Vijayan, R.K.; Castellano-Gonzalez, G.; memon, M.A.; Braidy, N.; Guillemin, G.J. Neuroprotective effect of natural products against Alzheimer´s disease. Neurochem. Res., 2012, 37(9), 1829-1842. http://dx.doi.org/10.1007/s11064-012-0799-9
107. Spencer, J.P.; Vafeiadou, K.; Williams, R.J.; vauzour, D. Neuroinflammation: modulation by flavonoids and mechanisms of action. Mol. Aspects Med., 2012, 33(1), 83-97. http://dx.doi.org/10.1016/j.mam.2011.10.016
108. Vauzour, D. Effect of flavonoids on learning, memory and neurocognitive performance: relevance and potential implications for Alzheimer´s disease pathophysiology. J. Sci. Food Agric., 2014, 94, 1042-1056. http://dx.doi.org/10.1002/jsfa.6473
109. Rege, S.D.; Geetha, T.; Griffin, G.D.; Broderick, T.L.; Babu, J.R. Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front. Aging Neurosci., 2014, 6, 218. http://dx.doi.org/10.3389/fnagi.2014.00218
110. Poulsen, M.M.; Fjeldborg, K.; ornstrup, M.J.; Kjaer, T.N.; Nohr, M.K.; Pedersen, S.B. Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes. Biochim. Biophys. Acta, 2015, 1852, 6, 1124-1136. http://dx.doi.org/10.1016/j.bbadis.2014.12.024
111. Bhullar, K.S.; Hubbard, B.P. Lifespan and healthspan extension by resveratrol. Biochim. Biophys. Acta, 2015, 1852, 6, 1209-1218. http://dx.doi.org/10.1016/j.bbadis.2015.01.012
112. Abraham, J.; Johnson, R.W. Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuvenation Res., 2009, 12(6), 445-453. http://dx.doi.org/10.1089/rej.2009.0888
113. Sebai, H.; Sani, M.; Ghanem-Boughanmi, N.; Aouani, E. Prevention of lipopolysaccharide-induced mouse lethality by resveratrol. Food Chem. Toxicol., 2010, 48, 1543-1549.http://dx. doi.org/10.1016/j.fct.2010.03.022
114. El-Sayed, N.S.; Bayan, Y. Possible role of resveratrol targeting estradiol and neprilysin pathways in lipopolysaccharide model of Alzheimer disease. Adv. Exp. Med. Biol., 2015, 822, 107-108. http://dx.doi.org/10.1007/978-3-319-08927-0_12
115. Noorafshan, A.; Ashkani-Esfahani, S.A review on therapeutic effects of curcumin. Curr. Pharm. Des., 2013, 19(11), 2032-2046. http://dx.doi.org/10.2174/1381612811319110006
116. Lee, W.H.; Loo, C.Y.; Bebawy, M.; Luk, F.; Mason, R.S.; Rohanizadeh, R. Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr. Neuropharmacol., 2013, 11(4), 338-378. http://dx.doi.org/10.2174/1570159X11311040002
117. Furst, R.; Zundorf, I. Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediators Inflamm., 2014, 2014, 146832.
118. Shanmugam, M.K.; Rane, G.; Kanchi, M.M.; Arfuso, F.; Chinnathambi, A.; Zayed, M.E.; Alharbi, S.A.; Tan, B.K.; Kumar, A.P.; Sethi, G. The multifaceted role of curcumin in cancer prevention and treatment. Molecules, 2015, 20(2), 2728-2769. http://dx.doi.org/10.3390/molecules20022728
119. Vallianou, N.G.; Evangelopoulos, A.; Schiraz, N.; Kazazis, C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res., 2015, 35(2), 645-651.
120. Begum, A.N.; Jones, M.R.; Lim, G.P.; Morihara, T.; Kim, P.; Heath, D.D.; Rock, C.L.; Pruitt, M.A.; Yang, F.; Hudspeth, B.; Hu, S.; Faull, K.F.; Teter, B.; Cole, G.M.; Frautschy, S.A. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer´s disease. J. Pharmacol. Exp. Ther., 2008, 326(1), 196-208. http://dx.doi.org/10.1124/jpet.108.137455
121. Wang, Z.; Zhang, Q.; Yuan, L.; Wang, S.; Liu, L.; Yang, X.; Li, G.; Liu, D. The effects of curcumin on depressive-like behavior in mice after lipopolysaccharide administration. Behav. Brain Res., 2014, 274, 282-290. http://dx.doi.org/10.1016/j.bbr.2014.08.018
122. Zhuang, X.; Xiang, X.; Grizzle, W.; Sun, D.; Zhang, S.; Axtell, R.; Ju, S.; Mu, J.; Zhang, L.; Steinman, L.; Miller, D.; Zhang, H.G. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther., 2011, 19(10), 1769-1779. http://dx.doi.org/10.1038/mt.2011.164
123. Nah, S.Y. Ginseng ginsenoside pharmacology in the nervous system: involvement in the regulation of ion channels and receptors. Front. Physiol., 2014, 5, 98. http://dx.doi.org/10.3389/fphys.2014.00098
124. Chen, W.Z.; Liu, S.; Chen, F.F.; Zhou, C.J.; Yu, J.; Zhuang, C.L.; Shen, X., Chen, B.C.; Yu, Z. prevention of postoperative fatigue syndrome in rat model by ginsenoside Rb1 via down-regulation of inflammation along NMDA receptor pathway in the hippocampus. Biol. Pharm. Bull., 2015, 38(2), 239-247. http://dx.doi.org/10.1248/bpb.b14-00599
125. Guan, N.; Huo, X.; Zhang, Z.; Zhang, S.; Luo, J.; Guo, W. Ginsenoside Rh2 inhibits metastasis of glioblastoma multiforme through Akt-regulated MMP13. Tumor Biol., 2015, DOI 10.1007/s13277-015-3387-1.
126. Miao, H.H.; Zhen, Y.; Ding, G.N.; Hong, F.X.; Xie, Z.C.; Tian, M. Ginsenoside Rg1 attenuates isoflurane-induced caspase-3 activation via inhibiting mitochondrial dysfunction. Biomed. Environ. Sci., 2015, 28(2), 116-126.
127. Lee, J.S.; Song, J.H.; Sohn, N.W.; Shin, J.W. Inhibitory effects of Ginsenoside Rb1 on neuroinflammation following systemic lipopolysaccharide treatment in mice. Phytother. Res., 2013, 27, 1270-1276. http://dx.doi.org/10.1002/ptr.4852
128. Ni, Y.F.; kuai, J.K.; Lu, Z.F.; Yang, G.D.; Fu, H.Y.; Wang, J.; Tian, F.; Yan, X.L.; Zhao, Y.C.; Wang, Y.J.; Jiang, T. Glycyrrhizin treatment is associated with attenuation of lipopolysaccharideinduced acute lung injury by inhibiting cyclooxygenase-2 and inducible nitric oxide synthase expression. J. Surg. Res., 2011, 165, e29-e35. http://dx.doi.org/10.1016/j.jss.2010.10.004
129. Ming, L.J.; Yin, A.C. therapeutic effects of glycyrrhizic acid. Nat. Prod. Commun., 2013, 8(3), 415-418.
130. Akman, T.; Guven, M.; Aras, A.B.; Ozkan, A.; sen, H.M.; Okuyucu, A.; Kalkan, Y.; Sehitoglu, I.; Silan, C.; Cosar, M. The neuroprotective effect of glycyrrhizic acid on an experimental model of focal cerebral ischemia in rats. Inflammation, 2015, DOI: 10.1007/s10753-015-0133-1. http://dx.doi.org/10.1007/s10753-015-0133-1
131. Schepetkin, I.A.; Kirpotina, L.N.; jakiw, L.; khlebnikov, A.I.; Blaskovich, C.L.; Jutila, M.A.; Quinn, M.T. Immunomodulatory activity of oenothein B isolated from Epilobium angustifolium. J. Immunol., 2009, 183(10), 6754-6766. http://dx.doi.org/10.4049/jimmunol.0901827
132. Kiss, A.K.; bazylko, A.; Filipek, A.; Granica, S.; Jaszewska, E.; Kiarszys, U.; kosmider, A.; Piwowarski, J. Oenothein B´s contribution to the anti-inflammatory and antioxidant activity of Epilobium sp. Phytomedicine, 2011, 18(7), 557-560. http://dx. doi.org/10.1016/j.phymed.2010.10.016
133. Azimi, H.; Khakshur, A.A.; Aghdasi, I.; Fallah-Tafti, M.; Abdollahi, M. A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflamm. Allergy Drug Targets, 2012, 11(3), 207-221. http://dx.doi.org/10.2174/187152812800392715
134. Suk, K. Regulation of neuroinflammation by herbal medicine and its implications for neurodegenerative diseases. Neurosignals, 2005, 14, 23-33. http://dx.doi.org/10.1159/000085383
135. Vafeiadou, K.; Vauzour, D.; Spencer, J.P. Neuroinflammation and its modulation by flavonoids. Endocr. Metab.Immune Disord. Drug Targets, 2007, 7(3), 211-224. http://dx.doi.org/10.2174/187153007781662521
136. Ha, S.K.; Moon, E.; Lee, P.; Ryu, J.H.; Oh, M.S.; Kim, S.Y. Acacetin attenuates neuroinflammation via regulation the response to LPS stimuli in vitro and in vivo. Neurochem. Res., 2012, 37, 1560-1567. http://dx.doi.org/10.1007/s11064-012-0751-z
137. Lee, Y.J.; Choi, D.Y.; Han, S.B.; Oh, K.W.; Hong, J.T. Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties. J. Nutr. Biochem., 2013, 24, 298-310. http://dx.doi.org/10.1016/j.jnutbio.2012.06.011
138. Wang, Y.J.; Zheng, Y.L.; Lu, J.; Chen, G.Q.; Wang, X.H.; Feng, J.; Ruan, J.; Sun, X.; Li, C.X.; Sun, Q.J. Purple sweet potato Color suppresses lipopolysaccharide-induced acute inflammatory response in mouse brain. Neurochem. Int., 2010, 56, 424-430. http://dx.doi.org/10.1016/j.neuint.2009.11.016
139. Mestas, J.; Hughes, C.C.W. Of mice and not men: differences between mouse and human immunology. J. Immunol., 2004, 172, 2731-2738. http://dx.doi.org/10.4049/jimmunol.172.5.2731
140. Seok, J.; Warren, H.S.; Cuenca, A.G.; Mindrinos, M.N.; Baker, H.V.; Xu, W.; Richards, D.R.; McDonald-Smith, G.P.; Gao, H.; Hennesy, L.; Finnerty, C.C.; Lopez, C.M.; Honari, S.; Moore, E.E.; Minei, J.P.; Cuschieri, J.; Bankey, P.E.; Johnson, J.L.; Sperry, J.; Nathens, A.B.; Billiar, T.R.; West, M.A.; Jeschke, M.G.; Klein, M.B.; Gamelli, R.L.; Gibran, N.S.; Brownstein, B.H.; Miller-Graziano, C.; Calvano, S.E.; Mason, P.H.; Cobb, J.P.; Rahme, R.G.; Lowry, S.F.; Maier, R.V.; Moldawer, L.L.; Herndon, D.N.; Davis, R.W.; Xiao, W.; Tompkins, R.G.; the Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. USA, 2013, 110(9), 3507-3512. http://dx.doi.org/10.1073/pnas.1222878110